Dyne Therapeutics Inc (DYN)
24.14
+0.44
(+1.88%)
USD |
NASDAQ |
Apr 26, 11:12
Dyne Therapeutics Enterprise Value: 1.819B for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 25, 2024 | 1.819B |
| April 24, 2024 | 1.924B |
| April 23, 2024 | 1.962B |
| April 22, 2024 | 1.915B |
| April 19, 2024 | 1.832B |
| April 18, 2024 | 1.815B |
| April 17, 2024 | 1.911B |
| April 16, 2024 | 1.896B |
| April 15, 2024 | 1.962B |
| April 12, 2024 | 1.996B |
| April 11, 2024 | 2.121B |
| April 10, 2024 | 2.076B |
| April 09, 2024 | 2.109B |
| April 08, 2024 | 2.082B |
| April 05, 2024 | 2.044B |
| April 04, 2024 | 2.045B |
| April 03, 2024 | 2.234B |
| April 02, 2024 | 2.159B |
| April 01, 2024 | 2.172B |
| March 28, 2024 | 2.204B |
| March 27, 2024 | 2.213B |
| March 26, 2024 | 2.072B |
| March 25, 2024 | 2.013B |
| March 22, 2024 | 2.191B |
| March 21, 2024 | 2.268B |
| Date | Value |
|---|---|
| March 20, 2024 | 2.164B |
| March 19, 2024 | 2.132B |
| March 18, 2024 | 2.031B |
| March 15, 2024 | 2.171B |
| March 14, 2024 | 2.064B |
| March 13, 2024 | 2.153B |
| March 12, 2024 | 2.098B |
| March 11, 2024 | 1.971B |
| March 08, 2024 | 1.939B |
| March 07, 2024 | 2.044B |
| March 06, 2024 | 2.072B |
| March 05, 2024 | 1.997B |
| March 04, 2024 | 2.148B |
| March 01, 2024 | 2.264B |
| February 29, 2024 | 2.082B |
| February 28, 2024 | 1.905B |
| February 27, 2024 | 1.874B |
| February 26, 2024 | 1.829B |
| February 23, 2024 | 1.727B |
| February 22, 2024 | 1.696B |
| February 21, 2024 | 1.708B |
| February 20, 2024 | 1.723B |
| February 16, 2024 | 1.737B |
| February 15, 2024 | 1.793B |
| February 14, 2024 | 1.841B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-97.94M
Minimum
Jun 02 2022
2.268B
Maximum
Mar 21 2024
509.02M
Average
425.54M
Median
Feb 21 2023
Enterprise Value Benchmarks
| Rocket Pharmaceuticals Inc | 1.627B |
| Solid Biosciences Inc | 198.80M |
| Avidity Biosciences Inc | 1.304B |
| Sana Biotechnology Inc | 1.669B |
| Tenaya Therapeutics Inc | 226.70M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -66.64M |
| Total Expenses (Quarterly) | 67.69M |
| EPS Diluted (Quarterly) | -1.09 |
| Earnings Yield | -16.32% |